UNDERSTAND MORE. FEAR LESS.

Understanding Your Cancer Diagnosis

A cancer diagnosis is more than the name of an organ.

Before treatment is chosen, doctors usually need to understand several things:

Two people may both be told they have “lung cancer” or “breast cancer” yet require very different treatments because their cancers may differ in subtype, stage and biology.

You do not need to understand every term at once. Your oncology team can help you put each part of the diagnosis into context.

Understand your cancer tests

Explore the Cancer Tests & Investigations — A Complete Patient Guide for biopsy, scans, blood tests, preparation, report interpretation and questions to ask your team.

Why is a biopsy so important?

A biopsy removes a small sample of tissue or cells so that a pathologist can examine it. For most solid cancers, a biopsy is the key test used to establish the exact diagnosis before treatment.

Imaging such as CT, MRI, PET-CT and ultrasound can show that an abnormal area exists, but imaging alone often cannot tell exactly what type of cancer it is.

A scan can show where an abnormality is. A biopsy helps tell us what it actually is.

The technique depends on the location and clinical situation. Options include:

  • needle biopsy, including fine-needle sampling
  • core biopsy, which obtains small pieces of tissue
  • endoscopic biopsy
  • surgical biopsy
  • bone-marrow examination for selected blood disorders

The treating team chooses the approach that is appropriate for that particular situation.

Does a biopsy make cancer spread?

For the vast majority of cancers, a properly performed biopsy does not cause the cancer to spread. Biopsies are routinely used worldwide because obtaining an accurate diagnosis is essential for choosing appropriate treatment.

Biopsy planning can be important in certain uncommon tumours or anatomical situations. Rare complications, including tumour seeding along a biopsy tract, are among the reasons the approach should be chosen by the treating team.

Explore more cancer myths and facts.

What is a pathology report?

A pathology report is the medical report prepared after a pathologist examines tissue or cells. Depending on the sample and tests performed, it may include:

  • the exact cancer type
  • histological subtype
  • tumour grade
  • whether cancer is present in sampled lymph nodes
  • surgical margins, when relevant
  • results of additional tests
  • selected biomarkers
  • molecular findings when tested

The pathology report is one of the most important documents in cancer care.

Pathology terminology can be complex. Ask your oncologist to explain the final diagnosis in plain language.

The organ is only part of the diagnosis

Cancer is often named after the organ where it began, but cancers arising in the same organ may be biologically very different.

Lung cancer

May include:

  • adenocarcinoma
  • squamous-cell carcinoma
  • small-cell lung cancer
  • other less common types

Breast cancer

May be characterised according to features such as:

  • hormone receptors
  • HER2
  • other biological characteristics

The exact subtype can affect which treatments are likely to work.

Explore breast cancer pathology and receptor results.

Grade and stage are not the same thing

Grade describes how the cancer cells look under the microscope and, for many cancers, gives information about how biologically aggressive the tumour may be.

Cancer cells that look more similar to normal cells may be described as more differentiated. Cells that look very abnormal may be described as poorly differentiated or undifferentiated.

Different cancers use different grading systems. Grade 1, 2 and 3 do not mean exactly the same thing in every cancer.

Stage ≠ Grade

Grade describes the appearance and biological behaviour of the cancer. Stage describes how far the cancer has spread.

What does “stage” mean?

Stage describes the extent of cancer in the body. It may take into account:

  • the size or extent of the primary tumour
  • involvement of nearby structures
  • regional lymph nodes
  • whether cancer has spread to distant organs

For many solid cancers, stage is described using the TNM system:

T — Tumour

Describes the size or extent of the main tumour.

N — Nodes

Describes whether regional lymph nodes contain cancer.

M — Metastasis

Describes whether cancer has spread to distant parts of the body.

The final TNM information may then be grouped into an overall stage. People often hear Stage I, Stage II, Stage III or Stage IV, but staging systems differ between cancer types.

Not every cancer uses the same staging system. Blood cancers, brain tumours and some other cancers may use different classifications.

Why can the stage change after surgery?

Clinical stage

Clinical stage is estimated before definitive surgery using information such as examination, scans, biopsy, endoscopy or other investigations.

Pathological stage

Pathological stage may be determined after surgery when the tumour and lymph nodes can be examined more completely under the microscope.

This means the final stage can sometimes be different from the stage suspected before surgery.

Lymph nodes and cancer

Lymph nodes are part of the body’s lymphatic and immune system. Cancer cells from some tumours may travel first to nearby lymph nodes.

Pathologists may describe examined nodes as:

  • negative — no cancer identified
  • positive — cancer cells identified

Cancer in nearby lymph nodes does not automatically mean Stage IV cancer.

Regional lymph-node involvement is incorporated differently into the staging system for different cancers. Stage IV generally refers to distant spread for most solid cancers, although staging rules vary by cancer type.

What is metastasis?

Metastatic cancer means that cancer cells have spread from the organ where the cancer started to a distant part of the body. For example, breast cancer that spreads to the liver remains breast cancer, not liver cancer.

Cancer is classified according to where it originally started, even after it spreads elsewhere.

Metastatic disease is usually considered advanced disease in solid cancers, but treatment and outlook vary enormously between different cancers and patients.

What does “margin” mean after surgery?

When a tumour is surgically removed, the pathologist also examines the edges of the removed tissue.

Negative or clear margin

No cancer is seen at the examined edge.

Positive or involved margin

Cancer cells are present at the examined edge.

The importance of margin status varies according to the cancer type, operation and other clinical factors. A positive margin does not always mean another operation is necessary.

The pathology report commonly contains information on margins and lymph nodes when these are relevant.

Biomarkers: looking beyond the microscope

Cancer cells may contain proteins, genes or other biological features that help doctors understand the tumour or select treatment. Depending on the context, these may be called biomarkers, molecular markers, tumour markers or molecular alterations.

Biomarker testing may sometimes help:

  • classify a cancer more precisely
  • estimate prognosis
  • identify a targeted treatment
  • help determine whether immunotherapy may be appropriate
  • identify eligibility for certain clinical trials

Not every patient needs every biomarker test.

Testing should depend on the cancer type, stage, treatment setting, available therapies and clinical guidelines.

Not all cancer tests are the same

IHC — Immunohistochemistry

IHC looks for specific proteins in cancer tissue. Depending on the cancer, IHC may be used to evaluate markers such as:

  • hormone receptors
  • HER2
  • mismatch repair proteins
  • PD-L1
  • proteins that help determine tumour origin

IHC usually answers a focused question about one or several specific proteins.

ISH / FISH — In-situ hybridisation

ISH or FISH can look for selected changes involving genes or chromosomes. FISH is a form of ISH that uses fluorescent signals. These methods may be used in particular situations to identify gene amplification, gene rearrangement or other specific chromosomal abnormalities. Not every patient requires FISH.

PCR

PCR-based testing looks for selected genetic alterations with a highly targeted laboratory method. It may be appropriate when doctors are looking for a particular known mutation or molecular change.

NGS — Next-generation sequencing

Next-generation sequencing can examine many genes or genetic regions from a tumour at the same time. It may identify molecular alterations that help guide targeted treatment, provide additional information about the tumour or identify possible clinical-trial options.

NGS is powerful, but it is not automatically necessary for every cancer patient.

Whether NGS is useful depends on:

  • the type of cancer
  • stage
  • available treatment options
  • the amount and quality of tumour tissue
  • what clinical question needs to be answered

Sometimes a single well-chosen IHC, FISH or PCR test provides exactly the information needed. In other situations, broader NGS testing is more useful.

Can biomarkers be tested from blood?

Some tumour DNA can circulate in the bloodstream. Testing this circulating tumour DNA is often called liquid biopsy or ctDNA testing.

Liquid biopsy may be useful in selected situations, particularly when:

  • tumour tissue is difficult to obtain
  • doctors are looking for certain actionable molecular alterations
  • it is being used for another validated clinical purpose

A negative liquid biopsy does not always mean that the tumour has no relevant mutation.

Some cancers release very little tumour DNA into the bloodstream. Therefore tissue testing may still be needed.

Tumour genetics vs inherited genetics

Tumour or somatic testing

Looks for changes inside the cancer cells. These changes may have developed during a person’s lifetime. This testing is often used to help understand the cancer or select treatment.

Germline or inherited genetic testing

Usually uses blood, saliva or another normal-cell sample. It asks whether a person was born with an inherited genetic alteration that may increase cancer risk.

Tumour NGS ≠ inherited genetic testing

Tumour NGS and inherited genetic testing are not the same test. Sometimes tumour testing raises suspicion of an inherited alteration, but separate germline testing may be needed to confirm it.

Who may need inherited genetic testing?

Inherited genetic testing may be considered when features such as the following suggest a hereditary cancer syndrome:

  • unusually young age at diagnosis
  • several relatives with related cancers
  • multiple cancers in the same person
  • particular cancer types or tumour features
  • other guideline-defined criteria

The decision should be based on the cancer type, personal history, family history and established guidelines. For some cancer types, guidelines recommend testing even without a strong family history. Genetic counselling may be helpful before or after testing.

Are blood tumour markers enough to diagnose cancer?

Blood tests such as tumour markers can sometimes help in cancer care, but an abnormal tumour marker alone usually cannot diagnose cancer.

Tumour markers may be elevated for non-cancerous reasons, and some people with cancer may have normal tumour-marker levels.

Depending on the cancer, tumour markers may be used along with clinical examination, imaging, pathology and other tests for purposes such as monitoring disease or treatment response.

Routine blood tests cannot reliably exclude cancer. Read about warning signs and appropriate screening; screening and investigating symptoms serve different purposes.

Same organ. Different cancer biology.

Two people may both have lung cancer. One may have an early-stage tumour suitable for surgery, while another may have metastatic disease requiring systemic treatment.

Even among patients with the same stage, molecular features may lead to different treatment options.

Modern cancer treatment increasingly depends not only on where a cancer started, but also on its stage, pathology and biology.

Read Cancer Treatment Explained to understand how these factors shape a treatment plan.

Your diagnosis in one sentence

Ask your oncology team to explain your diagnosis in plain language, then work through these questions before treatment starts:

  1. What is the exact cancer type?
  2. Where did it start?
  3. What is the stage?
  4. What is the grade, if relevant?
  5. Are lymph nodes involved?
  6. Has it spread to distant organs?
  7. Which biomarkers have been tested?
  8. Which testing method was used — IHC, FISH/ISH, PCR, NGS or another method?
  9. Do I need any additional molecular or inherited genetic testing?
  10. What is the goal of treatment — cure, reducing recurrence risk, long-term control or symptom relief?

Before discussing a drug name, understand the diagnosis, stage and goal of treatment.

Five questions worth asking

  1. What is my exact diagnosis?
  2. What stage is the cancer?
  3. What does the pathology report tell us?
  4. Do I need biomarker or genetic testing, and which method will be used?
  5. What is the goal of treatment?

What does prognosis mean?

Prognosis describes the expected course or outlook of a disease. It may be influenced by:

  • cancer type
  • stage
  • grade
  • biological characteristics
  • general health
  • response to treatment

Population statistics describe groups of people. They cannot tell exactly what will happen to one individual patient.

If you want information about prognosis, discuss it with your treating oncologist in the context of your individual case.

Clarity before treatment

Cancer treatment begins with understanding exactly what is being treated.

A good treatment plan starts with the correct diagnosis, appropriate staging and the right tests for that particular cancer.

DiagnosisStageBiologyTreatment goalTreatment plan

Next: Understand how cancer treatment is chosen →

Sources & Medical Review

This educational page draws on the following National Cancer Institute resources:

Reference to these sources does not imply endorsement by, or affiliation with, the National Cancer Institute.

Medically reviewed by

Dr Hakeem Ansar Hussain

Medical Oncologist

Last medically reviewed:

Medical Disclaimer

The information on Cancer Aware is provided for general education and awareness only. It is not a substitute for consultation, diagnosis or treatment by a qualified healthcare professional. If you have persistent, worsening or concerning symptoms, please seek medical advice.

This page does not diagnose an individual or replace pathology review or consultation with an oncologist. Specific testing and treatment decisions depend on the individual case.

For lung-specific testing and treatment, explore the Lung Cancer guide.